Cargando…

Contemporary hormone therapy with LHRH agonists for prostate cancer: avoiding osteoporosis and fracture

INTRODUCTION: Prostate cancer is a large clinical burden across Europe. It is, in fact, the most common cancer in males, accounting for more than 92,300 deaths annually throughout the continent. Prostate cancer is androgen-sensitive; thus an androgen deprivation therapy (ADT) is often used for treat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wilson, Hannah C.P., Shah, Syed I.A., Abel, Paul D., Price, Patricia, Honeyfield, Lesley, Edwards, Steve, Abel, Richard L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Polish Urological Association 2015
Materias:	Review Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4526606/ https://www.ncbi.nlm.nih.gov/pubmed/26251735 http://dx.doi.org/10.5173/ceju.2015.513

Ejemplares similares

LHRH agonists and the prevention of breast and ovarian cancer.
por: Pike, M. C., et al.
Publicado: (1989)

Switching from an LHRH Antagonist to an LHRH Agonist: A Case Report of 10 Finnish Patients with Advanced Prostate Cancer
por: Visapää, Harri
Publicado: (2017)

Expression of Luteinizing Hormone-Releasing Hormone (LHRH) and Type-I LHRH Receptor in Transitional Cell Carcinoma Type of Human Bladder Cancer
por: Szabó, Zsuzsanna, et al.
Publicado: (2021)

Hormonal treatment of pancreatic carcinoma: a phase II study of LHRH agonist goserelin plus hydrocortisone.
por: Philip, P. A., et al.
Publicado: (1993)

Transformation of a prostatic adenocarcinoma into squamous cell carcinoma after luteinizing hormone-releasing hormone (LHRH) agonist and radiotherapy treatment
por: Ichaoui, Hamza, et al.
Publicado: (2019)

Subclinical leprosy manifesting as a reversal reaction after LHRH agonist administration
por: Carmo, R.L.M.L., et al.
Publicado: (2018)

A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol
por: Langley, Ruth E., et al.
Publicado: (2016)

LHRH analogues and breast cancer.
por: Korkut, E., et al.
Publicado: (1991)

Synthesis of Radiolabeled Technetium- and Rhenium-Luteinizing Hormone-Releasing Hormone ((99m)Tc/Re-Acdien-LHRH) Conjugates for Targeted Detection of Breast Cancer Cells Overexpressing the LHRH Receptor
por: Calderon, Lindsay E., et al.
Publicado: (2021)

Substantial expression of luteinizing hormone-releasing hormone (LHRH) receptor type I in human uveal melanoma
por: Treszl, Andrea, et al.
Publicado: (2013)

Efficacy and Safety of AEZS-108 (LHRH Agonist Linked to Doxorubicin) in Women With Advanced or Recurrent Endometrial Cancer Expressing LHRH Receptors: A Multicenter Phase 2 Trial (AGO-GYN5)
por: Emons, Günter, et al.
Publicado: (2014)

Luteinizing hormone-releasing hormone receptor-mediated delivery of mitoxantrone using LHRH analogs modified with PEGylated liposomes
por: He, Yingna, et al.
Publicado: (2010)

Repeated vertebral augmentation for new vertebral compression fractures of postvertebral augmentation patients: a nationwide cohort study – how useful is the current clinical gold standard for fracture risk?
por: Wilson, Hannah CP, et al.
Publicado: (2015)

Squamous cell carcinoma of the prostate following treatment with an LHRH–agonist: a rare case of transformation of adenocarcinoma of the prostate
por: Al–Qassim, Zubair, et al.
Publicado: (2014)

AB166. Recovery of spermatogenesis of KH-465 herbal extract for LHRH agonist induced male infertility in rat
por: Park, Hyun Jun, et al.
Publicado: (2015)

Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125
por: Seitz, Stephan, et al.
Publicado: (2014)

AB100. Recovery of spermatogenesis of KH-465 herbal extracts mixture for LHRH agonist induced male infertility in rat
por: Park, Hyun Jun, et al.
Publicado: (2016)

Shrinkage of uterine fibroids by preoperative LHRH analogue injection.
por: McClelland, H. R., et al.
Publicado: (1992)

(99m)Tc-LHRH in tumor receptor imaging
por: Hao, Dawei, et al.
Publicado: (2017)

Enhanced Anti-Tumoral Activity of Methotrexate-Human Serum Albumin Conjugated Nanoparticles by Targeting with Luteinizing Hormone-Releasing Hormone (LHRH) Peptide
por: Taheri, Azade, et al.
Publicado: (2011)

Improving ovarian cancer imaging with LHRH-NBs: an experimental study
por: Li, Wenjuan, et al.
Publicado: (2016)

Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors
por: Curtis, Kelly K., et al.
Publicado: (2014)

Does Exist a Differential Impact of Degarelix Versus LHRH Agonists on Cardiovascular Safety? Evidences From Randomized and Real-World Studies
por: Sciarra, Alessandro, et al.
Publicado: (2021)

Nonrandomized Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone (LHRH) Analogs in Combination With Radiation Therapy in the CHHiP Trial
por: Tree, Alison, et al.
Publicado: (2022)

LHRH analogues in breast cancer: clever, but do we need them?
por: Smith, I. E.
Publicado: (1991)

Administering Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer 1–6 Days Compared to More Than 14 Days after the Start of LHRH Agonist Is Associated with Better Clinical Outcomes Due to Androgen Flare
por: Nasser, Nicola J., et al.
Publicado: (2022)

Evaluation of Hormonal Influence in Patients with Fractures Attributed to Osteoporosis
por: Malheiros-Souza, Danila, et al.
Publicado: (2021)

Clinical endocrinological evaluation of the gonadal axis (testosterone, LH and FSH) in prostate cancer patients switched from a GnRH antagonist to a LHRH agonist
por: Miyazawa, Yoshiyuki, et al.
Publicado: (2015)

Establishing an Animal Model of Secondary Osteoporosis by Using a Gonadotropin-releasing Hormone Agonist
por: Mohamad, Nur-Vaizura, et al.
Publicado: (2018)

Both radical prostatectomy following treatment with neoadjuvant LHRH agonist and estramustine and radiotherapy following treatment with neoadjuvant hormonal therapy achieved favorable oncological outcome in high-risk prostate cancer: a propensity-score matching analysis
por: Koie, Takuya, et al.
Publicado: (2014)

From contraception to cancer: a review of the therapeutic applications of LHRH analogues as antitumor agents.
por: Corbin, A.
Publicado: (1982)

Analogues of LHRH versus orchidectomy: comparison of economic costs for castration in advanced prostate cancer.
por: Rutqvist, L. E., et al.
Publicado: (1992)

Antitumor effects of cecropin B-LHRH’ on drug-resistant ovarian and endometrial cancer cells
por: Li, Xiaoyong, et al.
Publicado: (2016)

Small molecule targeted NIR dye conjugate for imaging LHRH receptor positive cancers
por: Roy, Jyoti, et al.
Publicado: (2019)

Hormone-Producing Tumours of the Gastrointestinal Tract - Contemporary Issues in Gastroenterolgy
por: Ahmed, Syed Rafeeq
Publicado: (1986)

Therapeutic dosing and targeting efficacy of Pt-Mal-LHRH towards triple negative breast cancer
por: Ndinguri, Margaret, et al.
Publicado: (2023)

Abiraterone acetate plus LHRH therapy versus abiraterone acetate while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled trial
por: Ohlmann, Carsten-Henning, et al.
Publicado: (2017)

Physicians' Attitudes to Contemporary Issues on Osteoporosis Management in Korea
por: Ha, Yong-Chan, et al.
Publicado: (2014)

Evaluating the prevalence and predictive factors of vasomotor and psychological symptoms in prostate cancer patients receiving hormonal therapy: Results from a single institution experience
por: Challapalli, Amarnath, et al.
Publicado: (2018)

Digital health interventions for osteoporosis and post-fragility fracture care
por: Gupta, Amit, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3mob6lv5oa2gks7201g0tpq56p